Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women

1995 ◽  
Vol 5 (3) ◽  
pp. 150-155 ◽  
Author(s):  
W. M. Kohrt ◽  
S. J. Birge
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Estrogen Treatment ◽  
Mineral Density ◽  
Differential Effects ◽  
Total Body

scholarly journals The Comparison of the Total Body Mass between Pre and Postmenopausal Women in Mosul City

2019 ◽  
pp. 1197-1205
Author(s):  
Khalid Ghanim Majeed ◽  
Husham A Thanon ◽  
Basim Idrees Dhannoon ◽  
Haitham B. Fathi
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Fat Mass ◽  
Mineral Content ◽  
Mineral Density ◽  
Total Body Mass ◽  
Post Menopause ◽  
The Mean ◽  
Total Body

In this research, we discussed bone density for women taking into consideration the method of research, we measure the total body mass of women in premenopausal and comparing it with postmenopausal, since the amount of the bone mineral content and bone mineral density, fat mass and lean mass.A cross sectional study conducted at DXA laboratory, Physiology Department, College of Medicine, University of Ninevah, Mosul-Iraq from Jan. 1 - Dec. 31, 2013. Since 174 healthy women recruited from reviewing of college medical academic center. They were divided into two groups: pre menopause group (n = 42) and post menopause group (n= 130). Detailed anthropometric data were gathered from study subjects. The mean age SD of pre-menopause group was (43.37 7.49) year while the mean age SD postmenopausal group (63.63 9.23) years .The T-score, Z-score, Bone Mineral Density (BMD), Bone Mineral Content (BMC), Fat Mass and Lean Mass were measured in the supine position by the use of DXA bone densitometer scanner type (STRATOS) from (DMS) group, France.Bone Mineral Content (BMC) was significantly lower in arm, rib, and thoracic spines. Bone Mineral Density (BMD) in arm, rib, leg and total were significantly low in postmenopausal women. Non-significant differences were noticed between both groups for lean mass. Postmenopausal women having more fat mass than pre menopause group. Both T-score and Z-score for pre menopause and post menopause groups were from class of osteopenia, but it was significantly lower in post menopause group (p-value =0.001, 0.008 respectively).Postmenopausal women were at higher risk of osteoporosis due to lowered Bone Mineral Density , T & Z scores.

scholarly journals Associations of Polyunsaturated Fatty Acid Intake with Bone Mineral Density in Postmenopausal Women

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Margaret Harris ◽  
Vanessa Farrell ◽  
Linda Houtkooper ◽  
Scott Going ◽  
Timothy Lohman
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Secondary Analysis ◽  
Mineral Density ◽  
Dietary Pufa ◽  
Cross Sectional ◽  
Pufa Intake ◽  
Total Body

A secondary analysis of cross-sectional data was analyzed from 6 cohorts (Fall 1995–Fall 1997) of postmenopausal women (n=266;56.6±4.7years) participating in the Bone Estrogen Strength Training (BEST) study (a 12-month, block-randomized, clinical trial). Bone mineral density (BMD) was measured at femur neck and trochanter, lumbar spine (L2–L4), and total body BMD using dual-energy X-ray absorptiometry (DXA). Mean dietary polyunsaturated fatty acids (PUFAs) intakes were assessed using 8 days of diet records. Multiple linear regression was used to examine associations between dietary PUFAs and BMD. Covariates included in the models were total energy intake, body weight at year 1, years after menopause, exercise, use of hormone therapy (HT), total calcium, and total iron intakes. In the total sample, lumbar spine and total body BMD had significant negative associations with dietary PUFA intake atP<0.05. In the non-HT group, no significant associations between dietary PUFA intake and BMD were seen. In the HT group, significant inverse associations with dietary PUFA intake were seen in the spine, total body, and Ward’s triangle BMD, suggesting that HT may influence PUFA associations with BMD. This study is registered with clinicaltrials.gov, identifier:NCT00000399.

scholarly journals Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study

2006 ◽  
Vol 96 (6) ◽  
pp. 1140-1148 ◽  
Author(s):  
George Moschonis ◽  
Yannis Manios
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Quantitative Ultrasound ◽  
Dairy Products ◽  
The Other ◽  
Mineral Density ◽  
Skeletal Site ◽  
Total Body

The aim of the current study was to examine whether calcium supplementation could prevent bone loss in postmenopausal women or more favourable outcomes could be obtained via the consumption of dairy products fortified with calcium and vitamin D3. For this purpose changes in bone mineral density (BMD) at different skeletal sites, assessed by dual-energy X-ray absorptiometry, as well as in quantitative ultrasound (QUS) parameters of the calcaneus over 12 months were estimated. A population of 101 postmenopausal women (55–65 years old) was randomized into a dairy group (DG: n 39), receiving approximately 1200 mg calcium/d and 7·5 μg vitamin D3/d through fortified dairy products; a calcium-supplemented group (CaG: n 26) provided with a calcium supplement of 600 mg/d; and a control group (CG: n 36). Over the intervention period the DG was found to have more favourable changes in pelvis (P = 0·040), total spine (P < 0·001) and total body BMD (P < 0·001) than the other groups. A significant increase was also observed for DG in lumbar spine BMD (2·0 %; 95 % CI 0·5, 3·5) although it did not differentiate significantly compared to the other groups. No significant differences were observed with respect to the changes in QUS parameters. The current study revealed that recommended intakes of vitamin D3 and calcium via fortified dairy products for 12 months can induce favourable changes in pelvis, total spine and total body BMD in postmenopausal women but not in QUS parameters. No such favourable changes were observed via supplementation of calcium alone.

scholarly journals The effects of a 30-month dietary intervention on bone mineral density: The Postmenopausal Health Study

2010 ◽  
Vol 104 (1) ◽  
pp. 100-107 ◽  
Author(s):  
George Moschonis ◽  
Ioanna Katsaroli ◽  
George P. Lyritis ◽  
Yannis Manios
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Dairy Products ◽  
Dietary Intervention ◽  
Control Group ◽  
Mineral Density ◽  
Nutrition Counselling ◽  
Total Body

Low dietary Ca intake and vitamin D insufficiency have been implicated as part of the aetiology leading to osteoporosis. The aim of the present study was to examine the effects of a 30-month dietary intervention that combined supplementation of dairy products fortified with Ca and vitamin D3 and lifestyle and nutrition counselling sessions on bone mineral density (BMD) of postmenopausal women. Sixty-six postmenopausal women (aged 55–65 years) were randomised into a dietary group (DG; n 35), receiving daily and for the first 12 months 1200 mg Ca and 7·5 μg vitamin D3, while for the next 18 months of intervention 1200 mg Ca and 22·5 μg vitamin D3 through fortified dairy products, and a control group (CG; n 31) receiving neither counselling nor dairy products. The DG was found to have more favourable changes in arms (P < 0·001), total spine (P = 0·001) and total body BMD (P < 0·001) compared with the CG. Furthermore, a significant increase was observed for the DG in lumbar spine BMD (0·056; 95 % CI 0·009, 0·103), which was not found to differentiate significantly compared with the change observed in the CG (P = 0·075). In conclusion, the present study showed that intakes of vitamin D of about 22·5 μg/d and of Ca close to the recommended level of 1200 mg from fortified dairy foods for 30 months, with compliance ensured by lifestyle and nutrition counselling sessions, can induce favourable changes in arms, total spine and total body BMD of postmenopausal women.

scholarly journals The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

2009 ◽  
Vol 94 (2) ◽  
pp. 538-544 ◽  
Author(s):  
Andrew Grey ◽  
Mark J. Bolland ◽  
Diana Wattie ◽  
Anne Horne ◽  
Greg Gamble ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Proximal Femur ◽  
Controlled Trial ◽  
Mineral Density ◽  
Markers Of Bone Turnover ◽  
Total Body

Abstract Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known. Objective: Our objective was to determine the duration of antiresorptive action of a single 5-mg dose of iv zoledronate. Design, Setting, and Participants: We conducted a double-blind, randomized, placebo-controlled trial over 2 yr at an academic research center, in a volunteer sample of 50 postmenopausal women with osteopenia. Intervention: Intervention included 5 mg zoledronate. Main Outcome Measures: Biochemical markers of bone turnover and bone mineral density of the lumbar spine, proximal femur, and total body. Results: Compared with placebo, zoledronate treatment decreased mean levels of each of four markers of bone turnover by at least 38% (range 38–45%) for the duration of the study (P &lt; 0.0001 for each marker). After 2 yr, bone mineral density was higher in the zoledronate group than the placebo group by an average of 5.7% (95% confidence interval = 4.0–7.4) at the lumbar spine, 3.9% (2.2–5.7) at the proximal femur, and 1.7% (0.8–2.5) at the total body (P &lt; 0.0001 for each skeletal site). Between-groups differences in markers of bone turnover and bone mineral density were similar at 12 and 24 months. Mild secondary hyperparathyroidism was present throughout the study in the zoledronate group. Conclusion: The antiresorptive effects of a single 5-mg dose of zoledronate are sustained for at least 2 yr. The magnitudes of the effects on markers of bone turnover and bone mineral density are comparable at 12 and 24 months. Administration of zoledronate at intervals of up to 2 yr may be associated with antifracture efficacy; clinical trials to investigate this possibility are justified.

Sign in / Sign up

Export Citation Format

Share Document